Stephanie Bennett
Family Medicine · Macon, GANPI 1043086879
Payments from drug & device makers
Across 105 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$324
- AbbVie$306
- Novo Nordisk$287
- Lilly USA, LLC$173
- Bayer$129
- AstraZeneca$84
- plus $609 from 18 others
What the payments were for
- Food & beverage$1,913100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 23 | $324 |
| AbbVie | 15 | $306 |
| Novo Nordisk | 16 | $287 |
| Lilly USA, LLC | 10 | $173 |
| Bayer | 6 | $129 |
| AstraZeneca | 5 | $84 |
| Boehringer Ingelheim | 4 | $75 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $72 |
| Merck | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| Medtronic | 1 | $36 |
| GSK | 2 | $36 |
| Pfizer | 1 | $34 |
| Ardelyx, Inc. | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Mindray DS USA, Inc. | 1 | $28 |
| Kerecis Limited | 1 | $27 |
| Vertex | 1 | $25 |
| Scpharmaceuticals Inc. | 1 | $23 |
| Seqirus USA Inc | 1 | $22 |
| Corcept Therapeutics | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Exact Sciences | 1 | $13 |
How this compares
$1,913 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 77 | $87,046 |
| EliquisApixaban | 35 | $33,930 |
| OzempicSemaglutide | 17 | $23,281 |
| JardianceEmpagliflozin | 12 | $16,945 |
| JanuviaSitagliptin Phosphate | 15 | $14,780 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,802 |
| PremarinEstrogens, Conjugated | 14 | $4,363 |
| Gabapentin | 76 | $1,331 |
| Duloxetine Hcl | 53 | $1,318 |
| Omeprazole | 76 | $864 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $799 |
| Quetiapine Fumarate | 24 | $726 |
| Levothyroxine Sodium | 72 | $675 |
| Atorvastatin Calcium | 97 | $664 |
| Metoprolol Succinate | 44 | $655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $173 | $87,04677 claims |
| PfizerEliquis, Premarin | $34 | $38,29349 claims |
| Novo NordiskOzempic | $287 | $23,28117 claims |
| Boehringer IngelheimJardiance | $75 | $16,94512 claims |
| MerckJanuvia | $55 | $14,78015 claims |
| AstraZenecaBreztri Aerosphere | $84 | $10,80217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Macon
- Frederick BurtonMacon$66K
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.